{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:47:55Z","timestamp":1757702875498},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T00:00:00Z","timestamp":1441411200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Pfizer Medical Education Group"},{"name":"Bristol-Myers Squibb\/Pfizer Education Consortium"},{"name":"NIH\/NCATS","award":["8UL1TR000077-05"],"award-info":[{"award-number":["8UL1TR000077-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s11239-015-1276-5","type":"journal-article","created":{"date-parts":[[2015,9,5]],"date-time":"2015-09-05T06:57:09Z","timestamp":1441436229000},"page":"234-240","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation"],"prefix":"10.1007","volume":"41","author":[{"given":"Mark H.","family":"Eckman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,9,5]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/archinte.1995.00430050045005","volume":"155","author":"WM Feinberg","year":"1995","unstructured":"Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 155:469\u2013473","journal-title":"Analysis and implications. Arch Intern Med."},{"key":"1276_CR2","first-page":"2242","volume":"56","author":"PA Wolf","year":"1997","unstructured":"Wolf PA, Singer DE (1997) Preventing stroke in atrial fibrillation. Am Fam Physician 56:2242\u20132250","journal-title":"Am Fam Physician"},{"key":"1276_CR3","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/archinte.1987.00370090041008","volume":"147","author":"PA Wolf","year":"1987","unstructured":"Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 147:1561\u20131564","journal-title":"The Framingham Study. Arch Intern Med."},{"key":"1276_CR4","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM198709103171104","volume":"317","author":"SL Kopecky","year":"1987","unstructured":"Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, Frye RL (1987) The natural history of lone atrial fibrillation. A population-based study over three decades. The New England journal of medicine. 317:669\u2013674","journal-title":"The New England journal of medicine."},{"key":"1276_CR5","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","volume":"285","author":"AS Go","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of Diagnosed Atrial Fibrillation in Adults: national Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 285:2370\u20132375","journal-title":"JAMA"},{"issue":"1","key":"1276_CR6","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5339\/gcsp.2014.2","volume":"2014","author":"RA Kaba","year":"2014","unstructured":"Kaba RA, Ahmed O, Cannie D (2014) Response to \u2018Lack of reversibility for NOACs\u2019. Glob Cardiol Sci Pract 2014(1):2","journal-title":"Glob Cardiol Sci Pract"},{"issue":"1","key":"1276_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5339\/gcsp.2014.1","volume":"2014","author":"S Al-Kindi","year":"2014","unstructured":"Al-Kindi S (2014) Lack of reversibility for NOACs. Glob Cardiol Sci Pract 2014(1):1","journal-title":"Glob Cardiol Sci Pract"},{"key":"1276_CR8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMp1302834","volume":"368","author":"MR Southworth","year":"2013","unstructured":"Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368:1272\u20131274","journal-title":"N Engl J Med"},{"key":"1276_CR9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1161\/CIRCOUTCOMES.112.967299","volume":"5","author":"K Kirley","year":"2012","unstructured":"Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 5:615\u2013621","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"1276_CR10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/1472-6963-14-310","volume":"14","author":"A AbuDagga","year":"2014","unstructured":"AbuDagga A, Stephenson JJ, Fu AC, Kwong WJ, Tan H, Weintraub WS (2014) Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res. 14:310","journal-title":"BMC Health Serv Res."},{"key":"1276_CR11","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1365-2753.2012.01886.x","volume":"19","author":"C Huang","year":"2013","unstructured":"Huang C, Siu M, Vu L, Wong S, Shin J (2013) Factors influencing doctors\u2019 selection of dabigatran in non-valvular atrial fibrillation. J Eval Clin Pract. 19:938\u2013943","journal-title":"J Eval Clin Pract."},{"key":"1276_CR12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1185\/03007995.2013.879529","volume":"30","author":"N Schoof","year":"2014","unstructured":"Schoof N, Schnee J, Schneider G, Gawlik M, Zint K, Clemens A, Bartels DB (2014) Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin 30:795\u2013804","journal-title":"Curr Med Res Opin"},{"key":"1276_CR13","doi-asserted-by":"crossref","first-page":"e000535","DOI":"10.1161\/JAHA.113.000535","volume":"2","author":"BA Steinberg","year":"2013","unstructured":"Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM (2013) Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2:e000535","journal-title":"J Am Heart Assoc."},{"key":"1276_CR14","unstructured":"NICE Implementation Collaborative (2014) NICE Implementation collaborative consensus\u2014supporting local implementation of nice guidance on the use of the novel (non-vitamin K antagonist) oral anticoagulants in non-valvular atrial fibrillation. National Institute for Health and Care Excellence"},{"key":"1276_CR15","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/imj.12448","volume":"44","author":"H Tran","year":"2014","unstructured":"Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C (2014) New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural\/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 44:525\u2013536","journal-title":"Intern Med J."},{"key":"1276_CR16","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","volume":"141","author":"A Holbrook","year":"2012","unstructured":"Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH (2012) Evidence-based management of anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e152S\u2013e184S","journal-title":"Chest"},{"key":"1276_CR17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/archinte.164.8.880","volume":"164","author":"J Rosand","year":"2004","unstructured":"Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM (2004) The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 164:880\u2013884","journal-title":"Arch Intern Med"},{"key":"1276_CR18","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1161\/STROKEAHA.112.652065","volume":"43","author":"D Dowlatshahi","year":"2012","unstructured":"Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, Wasserman JK, Poon MC, Coutts SB (2012) Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 43:1812\u20131817","journal-title":"Stroke"},{"key":"1276_CR19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1001\/archneur.65.10.1320","volume":"65","author":"AY Zubkov","year":"2008","unstructured":"Zubkov AY, Mandrekar JN, Claassen DO, Manno EM, Wijdicks EF, Rabinstein AA (2008) Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol 65:1320\u20131325","journal-title":"Arch Neurol"},{"key":"1276_CR20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11886-014-0480-9","volume":"16","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ (2014) Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep 16:480","journal-title":"Curr Cardiol Rep"},{"key":"1276_CR21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nm0313-251","volume":"19","author":"E Dolgin","year":"2013","unstructured":"Dolgin E (2013) Antidotes edge closer to reversing effects of new blood thinners. Nat Med 19:251","journal-title":"Nat Med"},{"key":"1276_CR22","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1076029614545211","volume":"21","author":"J Ebright","year":"2014","unstructured":"Ebright J, Mousa SA (2014) Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Thromb Hemost 21:105\u2013114","journal-title":"Clin Appl Thromb Hemost"},{"key":"1276_CR23","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","volume":"19","author":"G Lu","year":"2013","unstructured":"Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19:446\u2013451","journal-title":"Nat Med"},{"key":"1276_CR24","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","volume":"121","author":"F Schiele","year":"2013","unstructured":"Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554\u20133562","journal-title":"Blood"},{"key":"1276_CR25","author":"A Enriquez","year":"2015","unstructured":"Enriquez A, Lip GY, Baranchuk A (2015) Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace. doi: 10.1093\/europace\/euv030","journal-title":"Europace"},{"issue":"6","key":"1276_CR26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack CV Jr, Reilly PA, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373(6):511\u2013520","journal-title":"N Engl J Med"},{"key":"1276_CR27","doi-asserted-by":"crossref","first-page":"A10","DOI":"10.1161\/atvb.33.suppl_1.A10","volume":"33","author":"M Crowther","year":"2013","unstructured":"Crowther M, Kitt M, McClure M, Sinha U, Lu G, Karbarz MJ (2013) Randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors. Arterioscler Thromb Vas Biol 33:A10","journal-title":"Arterioscler Thromb Vas Biol"},{"key":"1276_CR28","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V122.21.3636.3636","volume":"122","author":"M Crowther","year":"2013","unstructured":"Crowther M, Vandana M, Kitt M, Genmin L, Conley PB, Hollenbach SJ, Castillo J, Hutchaleelaha A, Karbarz MJ, Lin J, Barron L, Russell S, Levy G, Connolly S, Curnutte JT (2013) A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors. Blood 122:3636","journal-title":"Blood"},{"issue":"AS20","key":"1276_CR29","first-page":"21","volume":"11","author":"M Crowther","year":"2013","unstructured":"Crowther M, Kitt M, Lorenz T, Mathur V, Lu G, Hutchaleelaha A (2013) A phase 2 randomized, double-blind, placebo controlled trial of PRT4445, a novel, uniersal antidote for direct and indirect Factor Xa inhibitors. J Thromb Haemost 11(AS20):21","journal-title":"J Thromb Haemost"},{"key":"1276_CR30","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","volume":"371","author":"JE Ansell","year":"2014","unstructured":"Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141\u20132142","journal-title":"N Engl J Med"},{"key":"1276_CR31","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1161\/01.STR.27.9.1459","volume":"27","author":"TN Taylor","year":"1996","unstructured":"Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF (1996) Lifetime cost of stroke in the United States. Stroke; a journal of cerebral circulation. 27:1459\u20131466","journal-title":"Stroke; a journal of cerebral circulation."},{"key":"1276_CR32","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1161\/CIR.0b013e31823ac046","volume":"125","author":"VL Roger","year":"2012","unstructured":"Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB (2012) Heart disease and stroke statistics\u20132012 update: a report from the American Heart Association. Circulation 125:e2\u2013e220","journal-title":"Circulation"},{"key":"1276_CR33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.repc.2014.08.008","volume":"34","author":"J Ferreira","year":"2015","unstructured":"Ferreira J, Mirco A (2015) Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. Rev Port Cardiol 34:179\u2013191","journal-title":"Rev Port Cardiol"},{"key":"1276_CR34","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jval.2013.01.009","volume":"16","author":"D Coyle","year":"2013","unstructured":"Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA (2013) Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 16:498\u2013506","journal-title":"Value Health."},{"key":"1276_CR35","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3111\/13696998.2012.680555","volume":"15","author":"S Deitelzweig","year":"2012","unstructured":"Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J (2012) Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 15:776\u2013785","journal-title":"J Med Econ."},{"key":"1276_CR36","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1161\/STROKEAHA.111.000402","volume":"44","author":"AR Harrington","year":"2013","unstructured":"Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC (2013) Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44:1676\u20131681","journal-title":"Stroke"},{"key":"1276_CR37","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40273-014-0246-7","volume":"33","author":"A Janzic","year":"2014","unstructured":"Janzic A, Kos M (2014) Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 33:395\u2013408","journal-title":"Pharmacoeconomics."},{"key":"1276_CR38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/02729890122062532","volume":"21","author":"MH Eckman","year":"2001","unstructured":"Eckman MH (2001) Patient-centered decision making: a view of the past and a look toward the future. Med Decis Making 21:241\u2013247","journal-title":"Med Decis Making"},{"key":"1276_CR39","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","volume":"141","author":"JJ You","year":"2012","unstructured":"You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e531S\u2013e575S","journal-title":"Chest"},{"key":"1276_CR40","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJM198205273062103","volume":"306","author":"BJ McNeil","year":"1982","unstructured":"McNeil BJ, Pauker SG, Sox J (1982) H.C., Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med 306:1259\u20131262","journal-title":"N Engl J Med"},{"key":"1276_CR41","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","author":"Atrial Fibrillation Investigators","year":"1994","unstructured":"Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449\u20131457","journal-title":"Arch Intern Med"},{"key":"1276_CR42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(89)80689-8","volume":"87","author":"CS Landefeld","year":"1989","unstructured":"Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144\u2013152","journal-title":"Am J Med"},{"key":"1276_CR43","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1161\/CIRCOUTCOMES.114.001163","volume":"7","author":"MH Eckman","year":"2014","unstructured":"Eckman MH, Wise RE, Speer B, Sullivan M, Walker N, Lip GY, Kissela B, Flaherty ML, Kleindorfer D, Khan F, Kues J, Baker P, Ireton R, Hoskins D, Harnett BM, Aguilar C, Leonard A, Prakash R, Arduser L, Costea A (2014) Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 7:680\u2013686","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"1276_CR44","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1185\/03007995.2015.1019608","volume":"31","author":"MH Eckman","year":"2015","unstructured":"Eckman MH, Wise RE, Naylor K, Arduser L, Lip GYH, Kissela B, Flaherty M, Kleindorfer D, Khan F, Schauer DP, Kues J, Costeai A (2015) Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for Shared Decision Making. Curr Med Res Opin 31:603\u2013614","journal-title":"Curr Med Res Opin"},{"key":"1276_CR45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","volume":"4","author":"MH Eckman","year":"2011","unstructured":"Eckman MH, Singer DE, Rosand J, Greenberg SM (2011) Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 4:14\u201321","journal-title":"Circ Cardiovasc Qual Outcomes"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1276-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-015-1276-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-015-1276-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T23:33:10Z","timestamp":1718062390000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-015-1276-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,5]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1007\/s11239-015-1276-5","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,5]]}}}